Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Pharmacokinetics and safety of single, multiple, and loading doses of fusidic acid in healthy subjects.

Still JG, Clark K, Degenhardt TP, Scott D, Fernandes P, Gutierrez MJ.

Clin Infect Dis. 2011 Jun;52 Suppl 7:S504-12. doi: 10.1093/cid/cir174.

PMID:
21546627
2.

A randomized, double-blind phase 2 study comparing the efficacy and safety of an oral fusidic acid loading-dose regimen to oral linezolid for the treatment of acute bacterial skin and skin structure infections.

Craft JC, Moriarty SR, Clark K, Scott D, Degenhardt TP, Still JG, Corey GR, Das A, Fernandes P.

Clin Infect Dis. 2011 Jun;52 Suppl 7:S520-6. doi: 10.1093/cid/cir167.

PMID:
21546629
3.

Phase I clinical studies of the advanced glycation end-product (AGE)-breaker TRC4186: safety, tolerability and pharmacokinetics in healthy subjects.

Chandra KP, Shiwalkar A, Kotecha J, Thakkar P, Srivastava A, Chauthaiwale V, Sharma SK, Cross MR, Dutt C.

Clin Drug Investig. 2009;29(9):559-75. doi: 10.2165/11315260-000000000-00000.

PMID:
19663519
4.

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.

Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, Snyder K, Hilliard D, Tanaka W, Zeng W, Tanen M, Wang AQ, Chen L, Winchell G, Davies MJ, Ramael S, Wagner JA, Herman GA.

Clin Ther. 2006 Jan;28(1):55-72.

PMID:
16490580
5.

Population pharmacokinetics of fusidic acid: rationale for front-loaded dosing regimens due to autoinhibition of clearance.

Bulitta JB, Okusanya OO, Forrest A, Bhavnani SM, Clark K, Still JG, Fernandes P, Ambrose PG.

Antimicrob Agents Chemother. 2013 Jan;57(1):498-507. doi: 10.1128/AAC.01354-12. Epub 2012 Nov 12.

6.

Pharmacokinetics and tolerance of a new film-coated tablet of sodium fusidate administered as a single oral dose to healthy volunteers.

Macgowan AP, Greig MA, Andrews JM, Reeves DS, Wise R.

J Chemother. 1989 Jul;1(4 Suppl):593-6. No abstract available.

PMID:
16312548
7.
8.

Safety, tolerance, and preliminary pharmacokinetics of nefazodone after administration of single and multiple oral doses to healthy adult male volunteers: a double-blind, phase I study.

Barbhaiya RH, Marathe PH, Greene DS, Mayol RF, Shukla UA, Gammans RR, Pittman KA, Robinson D.

J Clin Pharmacol. 1995 Oct;35(10):974-84.

PMID:
8568015
9.

Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects.

Muralidharan G, Micalizzi M, Speth J, Raible D, Troy S.

Antimicrob Agents Chemother. 2005 Jan;49(1):220-9.

10.

Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor.

Moore KH, Cass LM, Dallow N, Hardman TC, Jones A, Boyce M, Prince WT.

Eur J Clin Pharmacol. 2001 Jan-Feb;56(11):805-11.

PMID:
11294370
11.

Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.

Vaughan D, Speed J, Medve R, Andrews JS.

Clin Ther. 2010 Jan;32(1):146-60. doi: 10.1016/j.clinthera.2010.01.006.

PMID:
20171420
12.

Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men.

van Troostenburg AR, Clark EV, Carey WD, Warrington SJ, Kerns WD, Cohn I, Silverman MH, Bar-Yehuda S, Fong KL, Fishman P.

Int J Clin Pharmacol Ther. 2004 Oct;42(10):534-42.

PMID:
15516022
13.

A first-in-human, randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study to assess the safety and tolerability of LFF571 in healthy volunteers.

Ting LS, Praestgaard J, Grunenberg N, Yang JC, Leeds JA, Pertel P.

Antimicrob Agents Chemother. 2012 Nov;56(11):5946-51. doi: 10.1128/AAC.00867-12. Epub 2012 Sep 10.

14.

Fusidic acid pharmacology, pharmacokinetics and pharmacodynamics.

Turnidge J.

Int J Antimicrob Agents. 1999 Aug;12 Suppl 2:S23-34. Review.

PMID:
10528784
15.
16.

Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.

O'Farrell AM, van Vliet A, Abou Farha K, Cherrington JM, Campbell DA, Li X, Hanway D, Li J, Guler HP.

Clin Ther. 2007 Aug;29(8):1692-705.

PMID:
17919550
17.

Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects.

Bence AK, Anderson EB, Halepota MA, Doukas MA, DeSimone PA, Davis GA, Smith DA, Koch KM, Stead AG, Mangum S, Bowen CJ, Spector NL, Hsieh S, Adams VR.

Invest New Drugs. 2005 Jan;23(1):39-49.

PMID:
15528979
18.

Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.

Chung DT, Tsai CY, Chen SJ, Chang LW, King CH, Hsu CH, Chiu KM, Tan HC, Chang YT, Hsu MC.

Antimicrob Agents Chemother. 2010 Jan;54(1):411-7. doi: 10.1128/AAC.00683-09. Epub 2009 Nov 2.

19.

Antibiotic activity in serum following single and repeated oral administration of sodium fusidate in volunteers.

Munkholm P, Hey H, Rasmussen SN, Johansen PB.

Eur J Drug Metab Pharmacokinet. 1994 Oct-Dec;19(4):337-41.

PMID:
7737235

Supplemental Content

Support Center